Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern...
Gespeichert in:
Veröffentlicht in: | British journal of psychiatry 2016-11, Vol.209 (5), p.361-365 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 365 |
---|---|
container_issue | 5 |
container_start_page | 361 |
container_title | British journal of psychiatry |
container_volume | 209 |
creator | Murray, Robin M. Quattrone, Diego Natesan, Sridhar van Os, Jim Nordentoft, Merete Howes, Oliver Di Forti, Marta Taylor, David |
description | Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose. |
doi_str_mv | 10.1192/bjp.bp.116.182683 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891867024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1192_bjp_bp_116_182683</cupid><sourcerecordid>2315619302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-408cc56972b2295a481df087b3c43ebbd028a00ed8f93216c4bd4ecfdd59b1a63</originalsourceid><addsrcrecordid>eNp1kE1LHDEcxkNR6tb2A3iRgBcvs-Zt8nISEW0FwUPrsYS8jTvLzGZMMof99sbuqlDwlH_C7__LwwPACUZLjBW5sOtpaac68yWWhEv6BSwwE6TBjLcHYIEQEg0mLToC33Je1ytlRHwFR0RIRJQQC_D39yrOg4dT3rpVb0rqc8nQBjjGFKAzc-njnKGxcS6wrAIc4uapKSGNcEpxWm0H40rv4JwDjB00m9L_U8X6mC-_g8PODDn82J_H4PH25s_1r-b-4efd9dV946hQpWFIOtdyJYglRLWGSew7JIWljtFgrUdEGoSCl52iBHPHrGfBdd63ymLD6TE433lrpuc55KLHPrswDGYTanyNpcKSC0RYRc_-Q9dxTpuaThOKW44VRaRSeEe5FHNOodNT6keTthoj_dq9rt1rO9WZ6133ded0b57tGPz7xlvZFaB7qRlt6v1T-Pj7c-0LE46SYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315619302</pqid></control><display><type>article</type><title>Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Alma/SFX Local Collection</source><source>Cambridge University Press Journals Complete</source><creator>Murray, Robin M. ; Quattrone, Diego ; Natesan, Sridhar ; van Os, Jim ; Nordentoft, Merete ; Howes, Oliver ; Di Forti, Marta ; Taylor, David</creator><creatorcontrib>Murray, Robin M. ; Quattrone, Diego ; Natesan, Sridhar ; van Os, Jim ; Nordentoft, Merete ; Howes, Oliver ; Di Forti, Marta ; Taylor, David</creatorcontrib><description>Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose.</description><identifier>ISSN: 0007-1250</identifier><identifier>EISSN: 1472-1465</identifier><identifier>DOI: 10.1192/bjp.bp.116.182683</identifier><identifier>PMID: 27802977</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Analysis ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - pharmacology ; Antipsychotics ; Brain research ; Brain structure ; Diabetes ; Dopamine ; Dopamine D2 receptors ; Drug dosages ; Drug use ; Health status ; Humans ; Long term ; Mental disorders ; Mortality ; NMR ; Nuclear magnetic resonance ; Nutrition research ; Physical training ; Psychiatrists ; Psychiatry ; Psychosis ; Psychotic Disorders - prevention & control ; Psychotropic drugs ; Schizophrenia ; Schizophrenia - prevention & control ; Secondary Prevention - standards ; Side effects</subject><ispartof>British journal of psychiatry, 2016-11, Vol.209 (5), p.361-365</ispartof><rights>Copyright © Royal College of Psychiatrists, 2016</rights><rights>The Royal College of Psychiatrists 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-408cc56972b2295a481df087b3c43ebbd028a00ed8f93216c4bd4ecfdd59b1a63</citedby><cites>FETCH-LOGICAL-c379t-408cc56972b2295a481df087b3c43ebbd028a00ed8f93216c4bd4ecfdd59b1a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0007125000245364/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,780,784,12846,27924,27925,30999,55628</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27802977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murray, Robin M.</creatorcontrib><creatorcontrib>Quattrone, Diego</creatorcontrib><creatorcontrib>Natesan, Sridhar</creatorcontrib><creatorcontrib>van Os, Jim</creatorcontrib><creatorcontrib>Nordentoft, Merete</creatorcontrib><creatorcontrib>Howes, Oliver</creatorcontrib><creatorcontrib>Di Forti, Marta</creatorcontrib><creatorcontrib>Taylor, David</creatorcontrib><title>Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?</title><title>British journal of psychiatry</title><addtitle>Br J Psychiatry</addtitle><description>Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose.</description><subject>Analysis</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotics</subject><subject>Brain research</subject><subject>Brain structure</subject><subject>Diabetes</subject><subject>Dopamine</subject><subject>Dopamine D2 receptors</subject><subject>Drug dosages</subject><subject>Drug use</subject><subject>Health status</subject><subject>Humans</subject><subject>Long term</subject><subject>Mental disorders</subject><subject>Mortality</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Nutrition research</subject><subject>Physical training</subject><subject>Psychiatrists</subject><subject>Psychiatry</subject><subject>Psychosis</subject><subject>Psychotic Disorders - prevention & control</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>Schizophrenia - prevention & control</subject><subject>Secondary Prevention - standards</subject><subject>Side effects</subject><issn>0007-1250</issn><issn>1472-1465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1LHDEcxkNR6tb2A3iRgBcvs-Zt8nISEW0FwUPrsYS8jTvLzGZMMof99sbuqlDwlH_C7__LwwPACUZLjBW5sOtpaac68yWWhEv6BSwwE6TBjLcHYIEQEg0mLToC33Je1ytlRHwFR0RIRJQQC_D39yrOg4dT3rpVb0rqc8nQBjjGFKAzc-njnKGxcS6wrAIc4uapKSGNcEpxWm0H40rv4JwDjB00m9L_U8X6mC-_g8PODDn82J_H4PH25s_1r-b-4efd9dV946hQpWFIOtdyJYglRLWGSew7JIWljtFgrUdEGoSCl52iBHPHrGfBdd63ymLD6TE433lrpuc55KLHPrswDGYTanyNpcKSC0RYRc_-Q9dxTpuaThOKW44VRaRSeEe5FHNOodNT6keTthoj_dq9rt1rO9WZ6133ded0b57tGPz7xlvZFaB7qRlt6v1T-Pj7c-0LE46SYg</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Murray, Robin M.</creator><creator>Quattrone, Diego</creator><creator>Natesan, Sridhar</creator><creator>van Os, Jim</creator><creator>Nordentoft, Merete</creator><creator>Howes, Oliver</creator><creator>Di Forti, Marta</creator><creator>Taylor, David</creator><general>Cambridge University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7TK</scope><scope>7XB</scope><scope>88G</scope><scope>88J</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201611</creationdate><title>Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?</title><author>Murray, Robin M. ; Quattrone, Diego ; Natesan, Sridhar ; van Os, Jim ; Nordentoft, Merete ; Howes, Oliver ; Di Forti, Marta ; Taylor, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-408cc56972b2295a481df087b3c43ebbd028a00ed8f93216c4bd4ecfdd59b1a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotics</topic><topic>Brain research</topic><topic>Brain structure</topic><topic>Diabetes</topic><topic>Dopamine</topic><topic>Dopamine D2 receptors</topic><topic>Drug dosages</topic><topic>Drug use</topic><topic>Health status</topic><topic>Humans</topic><topic>Long term</topic><topic>Mental disorders</topic><topic>Mortality</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Nutrition research</topic><topic>Physical training</topic><topic>Psychiatrists</topic><topic>Psychiatry</topic><topic>Psychosis</topic><topic>Psychotic Disorders - prevention & control</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>Schizophrenia - prevention & control</topic><topic>Secondary Prevention - standards</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, Robin M.</creatorcontrib><creatorcontrib>Quattrone, Diego</creatorcontrib><creatorcontrib>Natesan, Sridhar</creatorcontrib><creatorcontrib>van Os, Jim</creatorcontrib><creatorcontrib>Nordentoft, Merete</creatorcontrib><creatorcontrib>Howes, Oliver</creatorcontrib><creatorcontrib>Di Forti, Marta</creatorcontrib><creatorcontrib>Taylor, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>British journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, Robin M.</au><au>Quattrone, Diego</au><au>Natesan, Sridhar</au><au>van Os, Jim</au><au>Nordentoft, Merete</au><au>Howes, Oliver</au><au>Di Forti, Marta</au><au>Taylor, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?</atitle><jtitle>British journal of psychiatry</jtitle><addtitle>Br J Psychiatry</addtitle><date>2016-11</date><risdate>2016</risdate><volume>209</volume><issue>5</issue><spage>361</spage><epage>365</epage><pages>361-365</pages><issn>0007-1250</issn><eissn>1472-1465</eissn><abstract>Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>27802977</pmid><doi>10.1192/bjp.bp.116.182683</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1250 |
ispartof | British journal of psychiatry, 2016-11, Vol.209 (5), p.361-365 |
issn | 0007-1250 1472-1465 |
language | eng |
recordid | cdi_proquest_miscellaneous_1891867024 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Applied Social Sciences Index & Abstracts (ASSIA); Alma/SFX Local Collection; Cambridge University Press Journals Complete |
subjects | Analysis Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacology Antipsychotics Brain research Brain structure Diabetes Dopamine Dopamine D2 receptors Drug dosages Drug use Health status Humans Long term Mental disorders Mortality NMR Nuclear magnetic resonance Nutrition research Physical training Psychiatrists Psychiatry Psychosis Psychotic Disorders - prevention & control Psychotropic drugs Schizophrenia Schizophrenia - prevention & control Secondary Prevention - standards Side effects |
title | Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Should%20psychiatrists%20be%20more%20cautious%20about%20the%20long-term%20prophylactic%20use%20of%20antipsychotics?&rft.jtitle=British%20journal%20of%20psychiatry&rft.au=Murray,%20Robin%20M.&rft.date=2016-11&rft.volume=209&rft.issue=5&rft.spage=361&rft.epage=365&rft.pages=361-365&rft.issn=0007-1250&rft.eissn=1472-1465&rft_id=info:doi/10.1192/bjp.bp.116.182683&rft_dat=%3Cproquest_cross%3E2315619302%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2315619302&rft_id=info:pmid/27802977&rft_cupid=10_1192_bjp_bp_116_182683&rfr_iscdi=true |